Cargando…

The intra-tumoural stroma in patients with breast cancer increases with age

PURPOSE: The tumour microenvironment in older patients is subject to changes. The tumour–stroma ratio (TSR) was evaluated in order to estimate the amount of intra-tumoural stroma and to evaluate the prognostic value of the TSR in older patients with breast cancer (≥ 70 years). METHODS: Two retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vangangelt, Kiki M. H., Kramer, Claire J. H., Bastiaannet, Esther, Putter, Hein, Cohen, Danielle, van Pelt, Gabi W., Rakha, Emad A., Green, Andrew R., Tollenaar, Rob A. E. M., Mesker, Wilma E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985058/ https://www.ncbi.nlm.nih.gov/pubmed/31535319 http://dx.doi.org/10.1007/s10549-019-05422-6

Ejemplares similares

The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple‐negative breast cancer
por: Vangangelt, Kiki M.H., et al.
Publicado: (2020)

Standardization of the tumor-stroma ratio scoring method for breast cancer research
por: Hagenaars, Sophie C., et al.
Publicado: (2022)

Prognostic value of tumor–stroma ratio combined with the immune status of tumors in invasive breast carcinoma
por: Vangangelt, K. M. H., et al.
Publicado: (2017)

Tumour-stroma ratio outperforms tumour budding as biomarker in colon cancer: a cohort study
por: Smit, Marloes A., et al.
Publicado: (2021)

Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer
por: Zunder, Stéphanie M., et al.
Publicado: (2018)

Tumor stroma as contributing factor in the lymph node metastases process?
por: Mesker, Wilma E., et al.
Publicado: (2019)

The prognostic value of tumour–stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review
por: Kramer, C. J. H., et al.
Publicado: (2018)

Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study
por: Smit, Marloes, et al.
Publicado: (2019)

Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content
por: Sandberg, Tessa P., et al.
Publicado: (2018)

Erratum: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content
por: Sandberg, Tessa P., et al.
Publicado: (2019)

The Stroma Liquid Biopsy Panel Contains a Stromal-Epithelial Gene Signature Ratio That Is Associated with the Histologic Tumor-Stroma Ratio and Predicts Survival in Colon Cancer
por: Ravensbergen, Cor J., et al.
Publicado: (2021)

Deep learning based tumor–stroma ratio scoring in colon cancer correlates with microscopic assessment
por: Smit, Marloes A., et al.
Publicado: (2023)

Combined Assessment of the Tumor–Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer
por: Ravensbergen, Cor J., et al.
Publicado: (2021)

e-Learning for Instruction and to Improve Reproducibility of Scoring Tumor-Stroma Ratio in Colon Carcinoma: Performance and Reproducibility Assessment in the UNITED Study
por: Smit, Marloes A, et al.
Publicado: (2021)

Comment on: The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer
por: Mesker, W E, et al.
Publicado: (2015)

The role of artificial intelligence to quantify the tumour-stroma ratio for survival in colorectal cancer
por: Smit, Marloes A, et al.
Publicado: (2020)

Characteristics of tumour stroma in regional lymph node metastases in colorectal cancer patients: a theoretical framework for future diagnostic imaging with FAPI PET/CT
por: Polack, Meaghan, et al.
Publicado: (2022)

Tumor‐stroma ratio is associated with Miller‐Payne score and pathological response to neoadjuvant chemotherapy in HER2‐negative early breast cancer
por: Hagenaars, Sophie C., et al.
Publicado: (2021)

Serum N-glycan profiles differ for various breast cancer subtypes
por: Vreeker, Gerda C. M., et al.
Publicado: (2021)

The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development
por: Aljohani, Abrar I., et al.
Publicado: (2022)

Presence of a High Amount of Stroma and Downregulation of SMAD4 Predict for Worse Survival for Stage I–II Colon Cancer Patients
por: Mesker, Wilma E., et al.
Publicado: (2009)

Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations
por: van Pelt, G. W., et al.
Publicado: (2018)

Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer
por: Sandberg, Tessa P., et al.
Publicado: (2019)

Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers
por: Savva, Constantinos, et al.
Publicado: (2019)

The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
por: Althobiti, Maryam, et al.
Publicado: (2020)

Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer
por: Althobiti, Maryam, et al.
Publicado: (2021)

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
por: Aleskandarany, Mohammed, et al.
Publicado: (2015)

Connexin 43 is an independent predictor of patient outcome in breast cancer patients
por: Chasampalioti, Maria, et al.
Publicado: (2018)

Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2020)

Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer
por: Elsharawy, Khloud A., et al.
Publicado: (2020)

The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2021)

The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer
por: El Ansari, Rokaya, et al.
Publicado: (2020)

Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer
por: Kariri, Yousif, et al.
Publicado: (2022)

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis
por: Engels, C. C., et al.
Publicado: (2015)

The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS)
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers
por: Ahmad, Dena A. J., et al.
Publicado: (2016)

Biological and clinical significance of PARP1 protein expression in breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer
por: Kariri, Yousif A., et al.
Publicado: (2020)

Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy
por: Al-Subhi, Nouf, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jvjn2326h6mflgv5vq4dj5hrg0